Proactive specialist asset management
We provide venture, private equity or debt finance to regional businesses with growth ambition.
Mercia's preliminary results presentation 2022
Registration now open
Mercia is pleased to announce the registration details for the online investor presentation of the Group’s preliminary results to be held on Tuesday 5 July 2022
The presentation will be given by Dr Mark Payton, Chief Executive Officer, Martin Glanfield, Chief Financial Officer and Julian Viggars, Chief Investment Officer.
Questions can be submitted pre-event via the Investor Meets Company dashboard or at any time during the live presentation via the ‘Ask a Question’ function.
The Insight - Edition 4: The future of Deep Tech
Mercia is pleased to announce the publication of ‘The Insight’, Edition 4.
Once again, our quarterly newsletter provides a look into our operations and investment activity, with topical commentary from members of the Mercia team.
A UK leading regional asset manager
Our approach to investing has evolved over many years and is predicated on the cyclical nature of private capital deployment in the regions, where optimised returns are driven through deep industry experience and buying well through the cycle.
Mercia by numbers
c.£872million
AuM
AuM
1000+
Transactions
Transactions
c.400
Portfolio companies
Portfolio companies
c.100
Team members
Team members
Video: Mercia's 2021 preliminary results presentation
Mercia is a proactive specialist asset manager with a focus on regional businesses seeking capital to scale their businesses, offering investors a diversified range of products across debt and equity.
Our business model has been predicated on the cyclical nature of private capital deployment, where optimised returns are driven through deep industry experience and buying well through the cycle.
A trusted business partnering with high growth potential businesses, we have completed more than 1000 transactions in the last five years backing some of the most exciting businesses the UK regions has created, including Blue Prism, Native Antigen Company, nDreams, Voxpopme, OXGENE and Woodall Nicholson.
The execution of Mercia’s strategy is making good progress.
Ian Metcalfe
